Fero Industries, Inc. Acquisition Target, Pyro Pharmaceuticals Appoints New Board Member

CALGARY, Alberta--(Business Wire)--
Fero Industries, Inc. (OTCBB: FROI) (the "Company") Pyro Pharmaceuticals, Inc.
(Irvine, CA) is pleased to announce that Philip N. Sussman has recently been
appointed to the board of directors. Mr. Sussman is Managing Partner of The
Channel Group, LLC and has served as a member of senior management (Head of
Business Development, CFO, and CEO) of several public and private biotechnology
companies. Mr. Sussman has a B.S. in Physics from the State University of New
York at Stony Brook, Master of Science in Biotechnology from Manhattan College,
and an S.M. in Management with a concentration in Finance from the Sloan School
of Management, MIT.

"Phil provides a needed component to our board with his expertise in licensing,
business development, and corporate governance. He complements our other board
members, Carol L. Epstein, M.D., and Ving J. Lee, Ph.D.," said Alan M.
Schechter, Pyro's Chairman and CEO.

Dr. Epstein has over 25 years of experience in clinical drug development and
trials, regulatory affairs, toxicology, and drug licensing. She has worked for
both biotechnology companies and big pharma. Dr. Epstein has a B.S. from the
Massachusetts Institute of Technology and received her M.D. from Yale University
School of Medicine. She is board certified in Rheumatology and Internal
Medicine. Dr. Lee is a highly regarded medicinal chemist with expertise in
infectious disease. Dr. Lee spent 16 years in the infectious disease group at
Lederle Laboratories, the last 4 years as Head of the Infectious Disease
Chemistry department. Currently, Dr. Lee is the Chief Executive Officer and
Chief Scientific Officer for Adesis Inc., a private chemistry contract research
organization (New Castle, DE) and Chief Scientific Officer and Co-founder of
Limerick BioPharma (South San Francisco). Dr. Lee holds sixty issued patents on
various antibiotic compounds and anti-bacterial genes. Dr. Lee received his B.A.
in chemistry from Ohio State University and his M.S., and Ph.D. degrees in
chemistry from the University of Illinois-Urbana. He was also an NIH post-grad
fellow at the University of Illinois-Urbana and Harvard University. Mr.
Schechter also said, "with the addition of Mr. Sussman, we have a qualified
board in place to guide us through the merger with Fero Industries (Calgary,
Alberta) and set the strategic and operational direction of Pyro Pharmaceuticals
to achieve its mission of developing a new class of antibiotics."

Certain statements in this press release that are not historical facts are
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements may be identified by the use of
words such as "anticipate," "believe," "expect," "future," "may," "will,"
"would," "should," "plan," "projected," "intend," and similar expressions. Such
forward-looking statements, involve known and unknown risks, uncertainties and
other factors that may cause the actual results, performance or achievements of
Fero Industries, Inc. (the Company) to be materially different from those
expressed or implied by such forward-looking statements.

The Company's future operating results are dependent upon many factors,
including but not limited to the Company's ability to: (i) obtain sufficient
capital or a strategic business arrangement to fund its expansion plans; (ii)
build the management and human resources and infrastructure necessary to support
the growth of its business; (iii) competitive factors and developments beyond
the Company's control; and (iv) other risk factors discussed in the Company's
periodic filings with the Securities and Exchange Commission, which are
available for review at www.sec.gov under "Search for Company Filings."

For more information visit Pyro`s website at www.pyropharmaceuticals.com or
contact Michael Irving at Interactive Resources Group, Inc. at 1-866-998-9669
Ext.150.

Interactive Resources Group, Inc.
Michael Irving, 1-866-998-9669 Ext.150

Copyright Business Wire 2009